Furthermore, closer monitoring of immune activation markers like CD38 and HLA-DR in HAART-treated patients could help identify those at risk of immune dysfunction despite viral suppression, guiding personalized therapeutic strategies. This evidence concerns the gene CD38 and immune system disorder.